Late-onset Neutropenia in Patients with Rheumatoid Arthritis after Treatment with Rituximab

REFERENCES

1. 1.↵
   1. Tesfa D,
   2. Ajeganova S,
   3. Hägglund H,
   4. Sander B,
   5. Fadeel B,
   6. Hafström I,
   7. et al.

   Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011;63:2209–14.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Wolach O,
   2. Bairey O,
   3. Lahav M

   . Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine 2010;89:308–18.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Fukuno K,
   2. Tsurumi H,
   3. Ando N,
   4. Kanemura N,
   5. Goto H,
   6. Tanabashi S,
   7. et al.

   Late-onset neutropenia in patients treated with rituximab for non-Hodgkin’s lymphoma. Int J Hematol 2006;84:242–7.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Voog E,
   2. Morschhauser F,
   3. Solal-Céligny P

   . Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691–4.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Tesfa D,
   2. Gelius T,
   3. Sander B,
   4. Kimby E,
   5. Fadeel B,
   6. Palmblad J,
   7. et al.

   Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008;25:374–9.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Weng WK,
   2. Negrin RS,
   3. Lavori P,
   4. Horning SJ

   . Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2010;28:279–84.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Li SC,
   2. Chen YC,
   3. Evens AM,
   4. Lee CC,
   5. Liao HF,
   6. Yu CC,
   7. et al.

   Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 2010;85:810–2.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Dunleavy K,
   2. Hakim F,
   3. Kim HK,
   4. Janik JE,
   5. Grant N,
   6. Nakayama T,
   7. et al.

   B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106:795–802.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Besada E

   . Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al [letter]. Arthritis Rheum 2012;64:596–7.

   OpenUrlCrossRefPubMed